Geron (GERN) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Geron (GERN) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.53% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -41.67% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -6,635.44% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -59.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.17% |
| Mar 31, 2026 | -1.11% |
| Dec 31, 2025 | 120.43% |
| Sep 30, 2025 | 2,509.39% |
| Jun 30, 2025 | 156.20% |
| Mar 31, 2025 | 53.30% |
| Dec 31, 2024 | -317.60% |
| Sep 30, 2024 | 88.25% |
| Jun 30, 2024 | 18.67% |
| Mar 31, 2024 | 119.14% |
| Dec 31, 2023 | 150.52% |
| Sep 30, 2023 | -147.90% |
| Jun 30, 2023 | -1,681.64% |
| Mar 31, 2023 | -687.42% |
| Dec 31, 2022 | 126.99% |
| Sep 30, 2022 | 282.06% |
| Jun 30, 2022 | -90.91% |
| Mar 31, 2022 | -20.10% |
| Dec 31, 2021 | 138.31% |
| Sep 30, 2021 | -139.86% |